Evidence map›Paper›PMID 11709300›Full record

ArticleAntimicrobial agents and chemotherapy2001

Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.

R G Nelson, A Rosowsky

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Phylogenetic Relationships and Structural Conservation ofInternational journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

R G NelsonDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California 94143, USA.
A Rosowsky
Dana-Farber Cancer Institute · USUniversity of California, San Francisco · US

Funding

LIPOPHILIC ANTIFOLATES AND AIDS OPPORTUNISTIC INFECTIONSR01AI029904 · NIAID · DANA-FARBER CANCER INSTITUTE · PI ROSOWSKY, ANDRE · 1990 to 2004
$1.8M
BIOCHEM.SCREENS FOR AGENTS EFF. AGAINST AIDS-RELATED OISN01AI035171 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI QUEENER, SHERRY F · 1993 to 1995
–
CRYPTOSPORIDIUM DHFR AS A CHEMOTHERAPEUTIC TARGETU01AI040319 · NIAID · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI NELSON, RICHARD G · 1996 to 1999
–
NIAID NIH HHS N01-AI35171NIAID NIH HHS R01 AI029904NIAID NIH HHS R0-AI29904NIAID NIH HHS UO1-AI40319
6 · The paper itself

Abstract

A structurally diverse library of 93 lipophilic di- and tricyclic diaminopyrimidine derivatives was tested for the ability to inhibit recombinant dihydrofolate reductase (DHFR) cloned from human and bovine isolates of Cryptosporidium parvum (J. R. Vásquez et al., Mol. Biochem. Parasitol. 79:153-165, 1996). In parallel, the library was also tested against human DHFR and, for comparison, the enzyme from Escherichia coli. Fifty percent inhibitory concentrations (IC(50)s) were determined by means of a standard spectrophotometric assay of DHFR activity with dihydrofolate and NADPH as the cosubstrates. Of the compounds tested, 25 had IC(50)s in the 1 to 10 microM range against one or both C. parvum enzymes and thus were not substantially different from trimethoprim (IC(50)s, ca. 4 microM). Another 25 compounds had IC(50)s of <1.0 microM, and 9 of these had IC(50)s of <0.1 microM and thus were at least 40 times more potent than trimethoprim. The remaining 42 compounds were weak inhibitors (IC(50)s, >10 microM) and thus were not considered to be of interest as drugs useful against this organism. A good correlation was generally obtained between the results of the spectrophotometric enzyme inhibition assays and those obtained recently in a yeast complementation assay (V. H. Brophy et al., Antimicrob. Agents Chemother. 44:1019-1028, 2000; H. Lau et al., Antimicrob. Agents Chemother. 45:187-195, 2001). Although many of the compounds in the library were more potent than trimethoprim, none had the degree of selectivity of trimethoprim for C. parvum versus human DHFR. Collectively, the results of these assays comprise the largest available database of lipophilic antifolates as potential anticryptosporidial agents. The compounds in the library were also tested as inhibitors of the proliferation of intracellular C. parvum oocysts in canine kidney epithelial cells cultured in folate-free medium containing thymidine (10 microM) and hypoxanthine (100 microM). After 72 h of drug exposure, the number of parasites inside the cells was quantitated by indirect immunofluorescence microscopy. Sixteen compounds had IC(50)s of <3 microM, and five of these had IC(50)s of <0.3 microM and thus were comparable in potency to trimetrexate. The finding that submicromolar concentrations of several of the compounds in the library could inhibit in vitro growth of C. parvum in host cells in the presence of thymidine (dThd) and hypoxanthine (Hx) suggests that lipophilic DHFR inhibitors, in combination with leucovorin, may find use in the treatment of intractable C. parvum infections.

Indexed as

Acquired Immunodeficiency SyndromeAnimalsAntiprotozoal AgentsCryptosporidium parvumEscherichia coliFolic Acid AntagonistsHumansProtein BindingStructure-Activity RelationshipTetrahydrofolate DehydrogenaseAntiprotozoal AgentsFolic Acid AntagonistsTetrahydrofolate Dehydrogenase

Identifiers

PMID11709300
PMCPMC90829
OpenAlexW2073350684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.